Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Brookfield Infrastructure Partners LP — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.93 (market cap $29.60B), while Brookfield Infrastructure Partners LP trades at $39.43 (market cap $18.10B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BIP | |
|---|---|---|
Market Cap | $29.60B | $18.10B |
Sector | Health | Industrials |
52-Week High | $491.22 | $42.62 |
52-Week Low | $205.48 | $29.81 |
Enterprise Value | $27.56B | $77.05B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Brookfield Infrastructure Partners (BIP) trades at $39.97, up 5.24% over 24 hours, with a bullish technical signal from moving averages. The stock shows strong analyst support with 13 buy ratings and a consensus price target of $44.67. Recent financials indicate revenue growth to $25.1 billion in 2026, though net income declined to $652 million. The company maintains a dividend yield with recent payouts of $0.46 per share and is undergoing corporate simplification to enhance shareholder value.
BIP presents a mixed outlook; attractive valuation metrics like EV/EBITDA of 6.97 and P/S of 0.72 suggest upside, but consecutive earnings misses and declining profitability margins pose risks. Investors may benefit from infrastructure demand and high dividend yields, yet should monitor execution on earnings targets and debt levels, with institutional sentiment leaning bullish amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
